Health Care Delivery

The FDA approved LEQEMBI IQLIK for once-weekly at-home subcutaneous initiation in early Alzheimer's disease based on IV and extension study data.

In this study, 13% of patients who stopped heart failure medications after successful AF ablation had HF deterioration vs none who continued treatment.

Stefanie Houseknecht, PharmD, explains how oncology pharmacists support biomarker testing, targeted therapy selection, and patient education in lung cancer care.

Ajay K. Nooka, MD, MPH, explains why CD38 exposure complicates trial applicability, how MRD could speed approvals, and what a dex-free future looks like.

Paul Hahn, MD, on what separates practice-changing retina therapies from niche ones, plus gene therapy and home-monitoring hurdles.

Kerry Rogers, MD, weighs sequencing risk against daily adverse effects like bruising and joint pain that quietly influence BTK inhibitor decisions.

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer treatment and survivorship.

Pharmacy eases lung cancer costs; pediatric cancer erases 40% income; BTKis widen CLL access; hospitals lag on translated aid; MN mandate ends NGS denials.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

COVID-19-related Medicare spending and health care use declined after acute infection, with minimal excess costs by weeks 13 to 40 after diagnosis.

Explore the biggest FDA PDUFA decisions expected in 2026, including gedatolisib, iberdomide, zidesamtinib, bepirovirsen, and anito-cel.

Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.

Ajai Chari, MD, addresses myeloma’s future: personalized care, shared decision-making, and why striving for a functional cure matters now.

The expanded approval, based on the phase 3 WIL-33 trial, gives children with von Willebrand disease access to routine bleeding prophylaxis.

Large biobank study suggests a polygenic risk score may improve prediction of idiopathic pulmonary fibrosis diagnosis and outcomes.

Ebola cases hit 1708 as unpaid health workers strike, further straining an outbreak response the World Health Organization says is outpacing containment.

Carl Regillo, MD, on missed wet AMD injections, treatment switching, and how gene therapy could ease chronic burden.

Erin L. Duffy, PhD, MPH, discusses her findings that nonprofit and system-affiliated hospitals have better multilingual access to financial aid documents.

Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care.

Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.

A secret shopper study found 9 in 10 online GLP-1 sellers issued prescriptions, often with minimal screening for eating disorders or clinical risk.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.